血清人附睾蛋白4、糖类抗原125检测在上皮性卵巢癌术预后评估中的临床意义

详细信息    查看全文 | 推荐本文 |

英文篇名：Clinical Significance of Serum Human Epididymis Protein 4 and Carbohydrate Antigen 125 in the Prognosis of Patients with Epithelial Ovarian Cancer 作者：刘玉洁 ; 刘杨 ; 吴波 英文作者：LIU Yujie;LIU Yang;WU Bo;Traditional Chinese Medicine Hospital of Suizhou City; 关键词：血清人附睾蛋白4 ; 糖类抗原125 ; 上皮性卵巢癌 ; 手术 ; 预后评估 英文关键词：Serum protein human epididymis 4;;Carbohydrate Antigen 125;;Epithelial ovarian cancer;;Operation;;Prognostic evaluation 中文刊名：ZYCX 英文刊名：Medical Innovation of China 机构：湖北省随州市中医医院;湖北医药学院附属随州医院; 出版日期：2019-02-05 出版单位：中国医学创新 年：2019 期：v.16;No.466 语种：中文; 页：ZYCX201904016 页数：4 CN：04 ISSN：11-5784/R 分类号：60-63

摘要

目的:研究血清人附睾蛋白4、糖类抗原125在上皮性卵巢癌术患者预后评估中的应用价值。方法:选择2015年11月-2016年10月于本院诊治的EOC术患者86例纳入EOC组,选择同期健康体检的正常女性86例纳入健康组。EOC组行标准肿瘤细胞减灭术联合化疗治疗,检测治疗前后两组HE4、CA125水平。以术后病理切片结果为金标准,评价HE4、CA125单独与联合检测EOC的敏感度(SEN)、特异度(SPE)、阳性预测值(PV+)、阴性预测值(PV-)等方法学结果。结果:EOC组患者缓解32例(37.21%),复发54例(62.79%),缓解及复发患者基线资料比较差异均无统计学意义(P>0.05)。化疗后1年,缓解、复发患者HE4、CA125水平均高于健康组,比较差异均有统计学意义(P<0.05);复发患者HE4、CA125水平均高于缓解患者,比较差异有统计学意义(P<0.05)。复发患者HE4、CA125单独检测EOC的SEN、SPE、PV+、PV-均低于联合检测。结论:EOC复发患者血清HE4、CA125显著升高,联合检测血清HE4、CA125对于评估EOC患者预后具有重要价值。
        Objective:To study the protein of serum human epididymis 4,carbohydrate Antigen 125 in patients with epithelial ovarian carcinoma prognostic value.Method:86 cases with EOC of the diagnosis and treatment in our hospital were selected from November 2015 to October 2016 as the EOC group,86 healthy normal women in the same period were selected as the healthy group.EOC group standard resection combined with chemotherapy in the treatment of tumor cells,the levels of HE4 and CA125 before and after treatment of two groups were tested.With postoperative pathological result as the gold standard,evaluation of HE4 and CA125 separate and joint detection sensitivity of the EOC(SEN),specificity(SPE),positive predictive value(PV+),negative predictive value(PV-)methodology results.Result:In EOC group,there were 32 cases of remission(37.21%)and 54 cases of recurrence(62.79%),there was no significant difference in baseline data between remission and recurrence patients(P>0.05).After chemotherapy 1 year,the levels of HE4 and CA125 in remission and recurrence cases were higher than those of health group,there were statistically significant difference(P<0.05).The levels of HE4 and CA125 in recurrence group were higher than those of remission group,there was statistically significant difference(P<0.05).The SEN,SPE,PV+ and PV- levels of EOC detected by HE4 and CA125 alone in recurrence patients were lower than those of combined detection. Conclusion:Serum HE4 and CA125 levels were significantly increased in patients with EOC recurrence.Combined detection of serum HE4 and CA125 levels is of great value in evaluating the prognosis of EOC patients.

引文

[1]惠慧,吴磊,杨新园.HE4检测对卵巢癌手术结果的预测分析[J].西部医学,2015,72(5):61-62.
    [2]马二玲,刘越飞,刘晓旭,等.HE4作为卵巢癌肿瘤标志物的研究进展[J].河北医药,2012,34(1):301-302.
    [3]Chang X,Ye X,Dong L,et al.Human epididymis protein4(HE4)as a serum tumor biomarker in patients with ovarian carcinoma[J].Int J Gynecol Cancer,2011,21(5):852-858.
    [4]周斌,刘世伟,高国璇,等.2016年NCCN乳腺癌临床实践指南(第1版)更新与解读[J].中国实用外科杂志,2016,36(10):1066-1072.
    [5]Cohen J G,White M,Cruz A,et al.In 2014,can we do better than CA125 in the early detection of ovarian cancer[J].World J Biol Chem,2014,5(3):286-300.
    [6]周娟.血清CA125动态变化对判断上皮性卵巢癌的疗效及预后价值[J].南昌大学学报:医学版,2014,54(2):38-40.
    [7]臧翊辰,陈爱平,丁朝,等.卵巢癌新辅助化疗患者CA125水平对临床结局的预测分析[J].现代妇产科进展,2015,24(3):217-219.
    [8]吴京,林珊娜,卓静.动态监测血清CA125对上皮性卵巢癌疗效及预后评估[J].河北医学,2012,18(10):1374-1376.
    [9]范连琴,范广忠.血清人附睾蛋白4和人类软骨糖蛋白39对卵巢癌的诊断价值[J].中国基层医药,2015,85(3):20-21.
    [10]曾磊.恶性肿瘤风险指数与肿瘤标志物用于盆腔包块良恶性诊断的临床价值[J].东南大学学报:医学版,2016,35(6):965-969.
    [11]李伟.血清HE4、FS及CA125在卵巢癌患者中的表达及其诊断价值[J].海南医学院学报,2013,311(12):70-71.
    [12]Jiang J,Bo D,Chang X,et al.Discrepant clinicopathologic characteristics and HE4 performance in typeⅠand typeⅡepithelial ovarian cancer[J].Int J Clin ExpMed,2015,8(11):21303-21310.
    [13]Steffensen K D,Waldstr?m M,Brandslund I,et al.Identification of high-risk patients by human epididymis protein4 levels during follow-up of ovarian cancer[J].Oncology Letters,2016,11(6):3967-3974.
    [14]刘倩.HE4和CA125监测老年卵巢癌转归的价值[J].标记免疫分析与临床,2011,18(6):374-379.
    [15]陈华干,杨婷,朱书宇,等.血清HE4联合CA125检测在卵巢癌术后复发中的诊断价值[J].中国妇幼保健,2016,31(18):3696-3698.
    [16]Karlan B Y,Thorpe J,Watabayashi K,et al.Use of CA125 and HE4 serum markers to predict ovarian cancer in elevated-risk women[J].Cancer Epidemiol Biomarkers Prev,2014,23(7):1383-1393.
    [17]Hasanbegovic L,Alicelebic S,Sljivo N.Comparison of specific ovarian tumor markers by elecsys analyzer 2010[J].Acta Inform Med,2015,23(2):86-89.
    [18]宋晓翠,张文珺,滕洪涛.血清HE4、CA125联合检测在卵巢癌术后复发诊断中的应用[J].山东医药,2012,52(14):75-76.
    [19]刘连红,罗建祥,徐月君,等.CA125和HE4蛋白在卵巢癌组织及血清中的表达及其临床意义探讨[J].重庆医学,2014,55(28):226-227.